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Investigating the survival features, and determinants of treatment and stage at presentation
in Iran
Methods
461 patients with pancreatic ductal adenocarcinoma (PC) were prospectively enrolled from
Shariati hospital, Tehran, Iran, between 2011–2018. All patients underwent endoscopic
ultrasonography, computed tomography scanning, and physical examination. Validated
questionnaire was completed for the participants and all were actively followed on monthly
basis.
Results
Median survival time was 6.5 months, and 1-, and 5-year survival rates were 26.2%, and
1.5%. Patients who were older (p<0.001), illiterate (p = 0.004), unmarried (p = 0.003), rural
inhabitant (p = 0.013), opium user (p = 0.039), and had lower body mass index (BMI) (p =
0.002) had lower overall survival. Tumors located in the head of pancreas were more com-
monly diagnosed at lower stages (p<0.001). Only 10.4% of patients underwent surgery who
were more commonly educated (p<0.001), married (p = 0.005), had a tumor located in the
head of pancreas (p = 0.016), and were diagnosed at lower stages (p<0.001). After adjust-
ment for potential confounders and risk factors, rural inhabitance (HR: 1.33 (95% CI: 1.01–
1.74)), having more symptoms (HR for each increasing symptom: 1.06 (1.02–1.11)), using
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opium (HR: 1.51 (1.04–2.20)), having a tumor located in the body of pancreas (HR: 1.33
(1.02–1.75)), and having an advanced tumor stage (HR: 2.07 (1.34–3.19)) remained signifi-
cantly associated with increased risk of mortality. After the adjusting for potential confound-
ers, we did not find significant relationships between smoking, alcohol intake, and BMI with
the risk of death among patients with pancreatic cancer.
Conclusions
Iranian patients with PC have very poor long-term survival. Besides tumor’s stage and loca-
tion, socioeconomic disparities could affect the probabilities of receiving treatment and/or
survival in these patients. Opium use is an independent risk factor for mortality among PC
patients in Iran.
Introduction
In 2018, an estimated 458,918 people across the world were diagnosed with pancreatic cancer
(PC), and 432,242 died of this disease, making it the 7th most common cause of cancer death
worldwide [1]. Poor prognosis remains one of the main characteristics of PC [1]; The burden
of PC is higher in the developed countries where the 5-year survival rates remain around 3–9%
without significant changes over the past decades [2–8].
With increasing longevity, socioeconomic developments, and lifestyle changes in the devel-
oping countries a substantial increase in the incidence of PC is expected in these regions [2, 3].
Currently, there is a significant lack of knowledge on the survival features and prognostic fac-
tors of PC in the developing countries. Most available information originate from retrospective
studies with limited sample size that are prone to different biases and are not generalizable [9,
10]. Further, we have previously identified using opium as a novel PC risk factor in popula-
tions where recreational use of opium is widespread [11, 12], however, it is not known if using
opium can also affect the survival of PC patients. Opium consumption was recently catego-
rized as a carcinogen to humans and opium pyrolysates were confirmed to have genotoxic
effects by the International Agency for Research of Cancer (IARC) [13]. Therefore, investigat-
ing the effect of opium use on the survival of PC patients is particularly important due to the
widespread use of opium and its derivatives (opiates) for managing cancer pain in the develop-
ing regions.
In this prospective study we analyze the clinical, pathological, therapeutic, and survival fea-
tures of 461 histologically confirmed PC cases to provide reliable information on different fea-
tures of PC in Iranian patients and to address the unmet medical needs and the possible
shortfalls in the management of PC in this region. We further assessed whether there is any
associations between opium consumption and risk of death among PC patients.
Materials and methods
Study population and design
This prospective study was performed on the patients with pancreatic adenocarcinoma that
were originally recruited to a large case-control study aimed to investigate the epidemiologic
features, clinical characteristics, and risk factors of pancreatic cancer in Iranian patients [11].
The detailed methods for this study have been previously described [11, 14]. Briefly, partici-
pants were recruited from Shariati hospital (a tertiary referral hospital) in Tehran, Iran,
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between January 2011 and January 2018. Patients who were suspicious for having a pancreatic
mass and were referred for performing endoscopic ultrasonography (EUS) with biopsy from
pancreatic tissue were invited to participate in the original case-control study. Upon enrol-
ment an informed written consent was obtained from the participants, then a validated and
reliable questionnaire was used to collect detailed information on demographics, socioeco-
nomic status, lifestyle and different exposures [14]. The participants were then referred for col-
lection of bio-samples and performing EUS, and in case of finding a mass or cystic lesions,
they underwent fine needle aspiration (FNA). The obtained samples were then reviewed by
one expert pathologist who was blinded to the questionnaire data. If the diagnosis of ductal
adenocarcinoma could not be finalized by hematoxylin/eosin staining, the samples were evalu-
ated using an immunohistochemistry panel to differentiate ductal adenocarcinoma from other
tumors. All participants who had histologically confirmed pancreatic ductal adenocarcinoma
were included in this study and were actively followed. This study was approved by the Institu-
tional Review Board and Ethics Committees of the Digestive Disease Research Institute of Teh-
ran University of Medical Sciences, and the National Institute for Medical Research
Development (approval number: IR NIMAD REC 1396 139).
Questionnaire data upon enrolment
Upon enrolment all participants were visited and interviewed by a trained general physician
who completed a detailed questionnaire for each participant, and performed a brief physical
examination and anthropometric measurements. Body mass index (BMI) was calculated at
enrolment for each participant by dividing the measured weight (kilograms) by the measured
height (meters) squared. We categorized the participants based on their BMI at enrolment as:
underweight (BMI < 18.5), normal (18.5� BMI< 25), overweight (25� BMI< 30), and
obese (BMI� 30).
The questionnaire contained 113 questions, collecting data on demographics, medical his-
tory, different exposures, and signs and symptoms of the current illness. The validity and reli-
ability of this questionnaire was previously confirmed in the pilot phase of this study [14].
The questionnaire included questions about regular consumption of opium, cigarettes, and
alcohol, the starting and ending ages for using each agent, and the frequency and amount of
consuming each agent. Regular use of opium and cigarettes were defined as using these agents
at least once per week for six consecutive months, while regular alcohol drinking was defined
as drinking alcohol at least once per month for six consecutive months. For opium use the par-
ticipants were further asked about the route (smoking/ingestion) and type (raw opium (teriak)
/ refined opium (shireh), opium dross (sukhteh)) of used opium. The detailed description of
this opium types are presented in S1 File. Most opium users in this study (93%) reported using
only raw opium, therefore we did not separate the analyses based on opium types. To assess
the effects of using opium we categorized the participants as “never opium users”, “former
opium users”, and “current opium users”. To assess the effects of smoking cigarettes we cate-
gorized the participants as “never smokers”, “former smokers”, and “current smokers”. Simi-
larly, to assess the effects of drinking alcohol we categorized the participants as “never alcohol
drinkers”, “former alcohol drinkers”, and “current alcohol drinkers”. Former opium users/
smokers/alcohol drinkers included participants who had previously used the corresponding
agent and had quitted using opium/smoking cigarettes/drinking alcohol at least for one year
before the interview.
The patients were interviewed before undergoing EUS and knowing the final diagnosis to
minimize the potential responder and interviewer bias that might possibly happen after identi-
fying the case status of the participants, and also to avoid receiving possible inaccurate
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responses due to EUS sedation. After performing the EUS, the endosonographist was asked to
complete the questionnaire data regarding the presence of any tumor in the pancreas, the size
and location of the tumor, and also any involvement of the vascular and lymphatic tissues.
All medical, imaging, and pathology documents were reviewed by an expert gastroenterolo-
gist to verify the stage of PC. Staging was performed using the information from EUS and con-
ventional computed tomography (CT) scan that were available on enrolment (before any
medical or surgical interventions) based on the TNM classification method that is proposed by
the American Joint Committee on Cancer (AJCC) (S2 File) [15].
Follow-up process
After confirming the diagnosis of pancreatic adenocarcinoma, the patients were introduced to
a multidisciplinary team that included gastroenterologist, oncologist, radiotherapist, radiolo-
gist, pathologist, and surgeon to receive the optimal management and treatments. All patients
have been actively followed through monthly telephone contacts to ascertain their vital status
and collect updated information on any new medical and therapeutic interventions they had
been receiving. In case of any new update, a team was assigned to collect copies of all newly
performed medical procedures, laboratory tests, imaging studies, treatment details, surgery
reports, and surgical pathology reports through contacting the patients, their relatives, and the
corresponding medical centers. The gathered information was then monthly reviewed by an
expert gastroenterologist to complete the follow-up data.
Statistical analysis
We used the Kaplan-Meier method to calculate the survival probabilities and construct the
survival curves, and used the log-rank test to assess the differences in Kaplan-Meier estimates.
Cox proportional hazards regression models were used to estimate hazard ratios (HRs) and
corresponding 95% confidence intervals (CIs) for assessing the prognostic effects of different
exposures on the survival of PC patients. The entry time was defined as the date at which the
participant was diagnosed with PC, and the exit time was the end of follow-up time, defined as
the date of death for those patients who died during the follow-up, and the date of last follow-
up for those who were still alive through the last follow-up on July 06, 2019.
The associations between different demographical, clinical, and tumoral characteristics
with PC stage and the received treatment were analyzed using the Chi-square test. The effects
of demographical, clinical, and tumor characteristics on the survival time were tested using
two multivariate Cox regression models. The first multivariate model (model-1) was adjusted
for the demographics including age (continuous), sex (male/female), formal education (ever/
never), marital status (married/single), and residence (urban/rural), while the second multi-
variate model (model-2) further included BMI at enrolment (underweight/normal/over-
weight/obese), number of symptoms upon diagnosis (continuous), smoking cigarettes (never/
former/current), using opium (never/former/current), drinking alcohol (never/former/cur-
rent), tumor location (head/body/tail), and stage of PC (I/II/III/IV). The final models were fur-
ther stratified by the received treatments (palliative / chemotherapy / surgery) that violated the
proportional hazard (PH) assumptions by showing time-varying effects. The PH assumption
was tested using Schoenfeld’s global test.
To assess reverse causality of opium use, we repeated the analysis after excluding all partici-
pants who started using opium during the last two years before diagnosis. All statistical analy-
ses were two-sided and performed using Stata statistical software version 14 (Stata
Corporation, College Station, Texas, USA).
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Results
Demographics
Four-hundred and sixty-one patients with histologically confirmed pancreatic ductal adeno-
carcinoma were enrolled in this prospective study. All patients were successfully followed. The
median survival time in this study was 6.5 months with a range of<1 month to 89.1 months,
while the 1-, 3-, and 5-year survival rates were 26.2%, 4.3% and 1.5%, respectively. The
mean ± SD of the participants’ age was 64.1 ± 11.5 years. Most participants were male (61.1%),
had formal education (59.4%), were married (81.7%), were overweight/obese (55.2%), and
lived in urban areas (80.0%). Of the participants, 36.5% reported ever smoking, 16.1% reported
ever use of opium, and 10.2% reported ever consumption of alcohol (Table 1).
Higher overall survival was observed in patients who were younger (p<0.001), educated
(p = 0.004), married (p = 0.003), overweight/obese (p = 0.002), lived in urban areas
(p = 0.019), and had never used opium (p = 0.039) (Table 1 and Fig 1).
Clinical symptoms
Details of clinical symptoms upon diagnosis are listed in S1 Table. Abdominal pain (82.4%)
and unintentional weight loss (81.3%) were the most common presenting symptoms. Further,
more than half of the patients had dark-colored urine (55.7%) and/or jaundice (52.2%). Of the
whole patients, 6.7% had presented with only one symptom, while 50% had at least six symp-
toms upon diagnosis (S1 Table).
Lower overall survival was observed in patients who had abdominal pain (p<0.001), unin-
tentional weight loss (p = 0.002), and constipation (p = 0.02) upon diagnosis. Having more
symptoms was also associated with lower overall survival (p = 0.013) (S1 Table).
Tumor and treatment characteristics
Most tumors (74.1%) originated from the head of pancreas. Of the participants, 9.5% were
diagnosed at stage I, 54.1% at stage II, 17.7% at stage III, and 18.6% were diagnosed at stage IV
of PC. Surgical resection was performed on 10.3% of the participants, while 56.7% received
chemotherapy either with surgery (adjuvant chemotherapy) (11.2% of those who received che-
motherapy) or without surgery (88.8% of those who received chemotherapy). 40.3% of the par-
ticipants only received palliative treatment (Table 1).
Higher overall survival was observed in patients who were diagnosed at lower stages
(p<0.001), those who received surgical resection of the tumor, and those who received chemo-
therapy (p<0.001) (Table 1).
Determinants of stage and the probability of receiving treatment
We did not find significant associations between demographics, smoking, opium use, and
alcohol intake with the stage of PC upon diagnosis (Table 2). Tumors that originated in the
head of pancreas were more commonly detected at lower stages, while tumors located in the
body and tail of pancreas were more commonly detected at higher stages (p<0.001) (Table 2).
Having abdominal pain was more common in patients who were diagnosed higher stage
tumors (p = 0.030). In contrary, having jaundice (p<0.001), dark-colored urine (p<0.001),
and pruritus (p<0.001) were more common among patients who were diagnosed with lower
stage tumors (Table 3).
Education and marital status were the only demographical factors that were associated with
the type of received treatment. Patients who were educated (p<0.001) and married (p = 0.005)
were more likely to receive surgery and/or chemotherapy than the illiterate and single patients
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Table 1. Estimates of overall survival rates by demographics and tumor characteristics among Iranian patients with pancreatic ductal adenocarcinoma.
Characteristics No (%) Median Survival (month) P-value ¶ 1 year Survival % 3 years survival % 5 years survival %
Total 461 (100) 6.5 26.2 4.3 1.5
Age (years) <0.001
<60 153 (33.1) 7.8 33.9 7.8 3.2
60–70 160 (34.7) 6.7 25.6 4.3 0.6
>70 149 (32.1) 5.2 18.9 0.6 0.0
Gender 0.36
Male 282 (61.1) 6.1 25.1 3.9 0.7
Female 179 (38.8) 6.9 27.9 5.0 2.7
Formal education 0.004 21.9 3.2 2.6
Never 187 (40.5) 5.2 29.2 5.1 0.7
Ever 274 (59.4) 7.2
Marital status 0.003
Married 377 (81.7) 6.8 28.1 5.3 1.8
Single 84 (18.2) 5.8 17.8 0.0 0.0
Residence 0.013
Urban 369 (80.0) 6.8 28.1 4.6 1.9
Rural 92 (19.9) 5.2 18.4 3.2 0.0
Body mass index � 0.002
Underweight 12 (2.6) 4.4 13.0 0 0
Normal 190 (42.1) 5.8 20.7 6.0 2.4
Overweight 166 (36.8) 8.3 34.7 8.3 3.2
Obese 83 (18.4) 6.9 35.4 18.1 12.5
Smoking status 0.88
Never 293 (63.5) 6.6 26.9 3.7 2.0
Former 59 (12.8) 6.8 27.1 3.3 0.0
Current 109 (23.6) 6.1 23.8 6.4 0.9
Opium use status 0.039
Never 387 (83.9) 6.9 27.9 4.6 1.8
Former 15 (3.2) 4.6 20.0 0.0 0.0
Current 59 (12.8) 4.9 16.9 3.3 0.0
Alcohol use status 0.51
Never 414 (89.80) 6.5 25.6 3.8 1.4
Former 24 (5.21) 4.9 25.0 12.5 4.1
Current 23 (4.99) 8.4 39.1 4.3 0.0
Tumor location 0.47
Head 342 (74.1) 6.8 28.6 5.2 1.7
Body 102 (22.1) 6.2 19.6 0.9 0.0
Tail 17 (3.6) 6.0 17.6 5.8 5.8
Tumor stage at diagnosis <0.001
I 44 (9.5) 9.5 38.6 9.0 6.8
II 249 (54.1) 7.1 27.7 5.6 1.2
III 82 (17.7) 7.2 29.2 1.2 0.0
IV 86 (18.6) 3.4 12.7 1.1 1.1
Primary treatment <0.001
Palliative 186 (40.3) 2.9 8.0 0.0 0.0
Chemotherapy 227 (49.2) 8.7 33.0 3.9 1.3
Surgical resection (+/- chemotherapy) 48 (10.4) 19.7 64.5 22.9 8.3
¶ Log-rank test P value
� Data on body mass index at enrolment is missing for 10 participants
https://doi.org/10.1371/journal.pone.0243511.t001
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(Table 4). Surgical resection was more commonly performed on the tumors that were diag-
nosed at early stages (p<0.001), and were located in the head of pancreas (p = 0.016) (Table 4).
Prognostic factors of pancreatic cancer survival
After adjustment for all potential confounders and risk factors, rural inhabitance (HR: 1.33,
95%CI: 1.01–1.74), having more symptoms at diagnosis (HR for each increase in the number
of symptoms: 1.06, 95%CI: 1.02–1.11), current opium use (HR: 1.51, 95%CI: 1.04–2.20), hav-
ing a tumor that is located in the body of pancreas (HR: 1.33, 95%CI: 1.02–1.75), and having
an advanced tumor stage (HR: 2.07, 95%CI: 1.34–3.19) remained significantly associated with
increased risk of mortality in patients with pancreatic ductal adenocarcinoma (Table 5).
Only three participants had started using opium in the last two years before diagnosis and
excluding these patients did not affect the observed results.
Discussion
This prospective study of 461 patients with histologically confirmed pancreatic ductal adeno-
carcinoma showed a very poor long-term survival among Iranian patients with PC. The 5-year
survival rates even in those who underwent surgical resection of the tumor were lower than
other countries. Tumor stage at diagnosis showed some associations with tumor location and
clinical symptoms. While, the type of received treatment differed across the strata of education
and marital status. After adjustment for potential confounders, rural inhabitance, having more
symptoms at diagnosis, current use of opium, having a tumor located in the body of pancreas,
and having an advanced tumor stage remained significantly associated with increased mortal-
ity risk among PC patients.
The median survival time in this study was 6.2 months, and the 1- and 5-year survival rates
were 26.2% and 1.5%, respectively. A survival analysis that included 202,584 European individuals
who were diagnosed with pancreatic cancer between 2000 and 2007, showed a median survival
time of 4.6 months, and an average 1- and 5-year survival rates of 25.9%, and 6.9% across Europe
[16, 17]. One- and five-year survival for patients diagnosed with pancreatic cancer during 2010–
2011 in England and Wales, were 20.8% and 3.3%, respectively [5], while 1- and 5-year survival
rates for patients who were diagnosed with pancreatic cancer during 2009–2015 in the United
States were 28% and 9.3%, respectively [18]. Finally, a recent analysis of 1,229,379 adults from 290
registries in 59 countries, showed that the 5-year net survival estimates for PC were generally in
Fig 1. Overall survival during the first 12 months of diagnosis in Iranian patients with pancreatic ductal adenocarcinoma. The survival curves
are stratified by a. having formal education, b. residence, c. ever use of opium.
https://doi.org/10.1371/journal.pone.0243511.g001
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the range 5–15% throughout 2000–2014 [19]. The median survival time and 1-year survival rates
in our study are comparable to the reported rates from the developed countries. However, despite
the high percentage of participants who were diagnosed at early stages, the 5-year survival rates in
our study are lower than the reported rates in other countries. These results show the need for
more efforts to improve the clinical management of PC patients in this region and to design
more studies aiming to investigate the underlying reasons of the observed poor long-term survival
in PC patients with early stage tumors and those who undergo surgical resection.
In the current study several indicators of socioeconomic status were related to survival and
the probability of receiving treatment in PC patients. Patients who lived in rural areas, were
Table 2. Associations between different demographics and tumor characteristics with the tumor stage at diagnosis among Iranian patients with pancreatic ductal
adenocarcinoma.
Characteristics Stages I & II (total n = 293) N (%) Stages III & IV (total n = 186) N (%) P-value ¶
Gender 0.36
Male 174 (59.3) 108 (64.2)
Female 119 (40.6) 60 (35.7)
Formal education 0.67
Ever 172 (58.7) 102 (60.7)
Never 121 (41.3) 66 (39.2)
Marital status 0.51
Married 237 (80.8) 140 (83.3)
Single 56 (19.1) 28 (16.6)
Residence 0.72
Urban 236 (80.5) 133 (79.1)
Rural 57 (19.4) 35 (20.8)
Body Mass Index � 0.39
Normal 8 (2.7) 4 (2.4)
Underweight 124 (43.2) 66 (40.2)
Overweight 109 (37.9) 57 (34.7)
Obese 46 (16.0) 37 (22.5)
Smoking 0.87
Never 188 (64.1) 105 (62.5)
Former 38 (12.9) 21 (12.5)
Current 67 (22.8) 42 (25.0)
Opium use 0.26
Never 247 (84.3) 140 (83.3)
Former 12 (4.1) 3 (1.7)
Current 34 (11.6) 25 (14.8)
Alcohol drinking 0.65
Never 266 (90.7) 148 (88.1)
Former 14 (4.7) 10 (5.9)
Current 13 (4.4) 10 (5.9)
Tumor location <0.001
Head 249 (84.9) 93 (55.3)
Body 39 (13.3) 63 (37.5)
Tail 5 (1.7) 12 (7.1)
¶ P value for chi-squared test
� Data on body mass index at enrolment is missing for 10 participants
https://doi.org/10.1371/journal.pone.0243511.t002
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illiterate, and did not have a partner had lower overall survival and were less likely to undergo
surgical resection of the tumor compared to patients who lived in urban areas, were education,
Table 3. Associations between different clinical symptoms with the tumor stage at diagnosis among Iranian patients with pancreatic ductal adenocarcinoma.
Characteristics Stages I & II (total n = 293) N (%) Stages III & IV (total n = 186) N (%) P-value ¶
Abdominal pain 0.030
No 60 (20.4) 21 (12.5)
Yes 233 (79.5) 147 (87.5)
Unintentional weight loss 0.24
No 60 (20.4) 27 (16.07)
Yes 233 (79.5) 141 (83.9)
Dark-colored urine <0.001
No 111 (37.8) 93 (55.3)
Yes 182 (62.1) 75 (44.6)
Jaundice <0.001
No 116 (39.5) 104 (61.9)
Yes 177 (60.4) 64 (38.1)
Light-colored stool 0.081
No 164 (55.9) 108 (64.2)
Yes 129 (44.0) 60 (35.7)
Constipation 0.57
No 177 (60.4) 97 (57.7)
Yes 116 (39.5) 71 (42.2)
Anorexia 0.14
No 170 (58.0) 109 (64.8)
Yes 123 (41.9) 59 (35.1)
Pruritus <0.001
No 155 (52.9) 123 (73.2)
Yes 138 (47.1) 45 (26.7)
Abdominal bloating 0.59
No 190 (64.8) 113 (67.2)
Yes 103 (35.1) 55 (32.7)
Nausea 0.65
No 207 (70.6) 122 (72.6)
Yes 86 (29.3) 46 (27.3)
Fever 0.422
No 221 (75.4) 121 (72.0)
Yes 72 (24.5) 47 (27.9)
Shivering 0.28
No 229 (78.1) 124 (73.8)
Yes 64 (21.8) 44 (26.1)
New onset diabetes � 0.83
No 260 (88.7) 148 (88.1)
Yes 33 (11.2) 20 (11.9)
Steatorrhea 0.50
No 263 (89.7) 154 (91.6)
Yes 30 (10.2) 14 (8.3)
¶ P value for chi-squared test
� New onset diabetes was defined as being diagnosed with diabetes mellitus in the recent 2 years
https://doi.org/10.1371/journal.pone.0243511.t003
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and had a partner. Further, rural residence remained an independent prognostic factor after
adjustment for other risk factors. The prognostic effects of socioeconomic status have been
also shown in the studies that were conducted in the developed countries including Denmark
[20], the United States [21, 22], Netherlands [6, 23], and Canada [24]. These results indicate
the requirement for strategies to enhance access to equipped healthcare centers in rural areas,
Table 4. Associations between different demographics and tumor characteristics with the type of received treatment among Iranian patients with pancreatic ductal
adenocarcinoma.
Characteristics Palliative N (%) (total n = 186) Chemotherapy N (%) (total n = 227) Surgery N (%) (total n = 48) P-value ¶
Gender 0.97
Male 113 (60.7) 139 (61.2) 30 (62.5)
Female 73 (39.2) 88 (38.7) 18 (37.5)
Formal education < 0.001
Ever 89 (47.8) 148 (65.2) 37 (77.0)
Never 97 (52.1) 79 (34.8) 11 (22.9)
Marital status 0.005
Married 139 (74.3) 195 (85.9) 43 (89.5)
Single 47 (25.2) 32 (14.1) 5 (10.4)
Residence 0.60
Urban 147 (79.0) 181 (79.7) 41 (85.4)
Rural 39 (20.9) 46 (20.2) 7 (14.5)
Body Mass Index � 0.083
Normal 8 (4.4) 3 (1.3) 1 (2.0)
Underweight 82 (45.5) 95 (42.6) 13 (27.0)
Overweight 62 (34.4) 84 (37.6) 20 (41.6)
Obese 28 (15.5) 41 (18.3) 14 (29.1)
Smoking 0.67
Never 122 (65.5) 143 (63.0) 28 (58.3)
Former 19 (10.2) 33 (14.5) 7 (14.5)
Current 45 (24.1) 51 (22.4) 13 (27.0)
Opium use 0.27
Never 149 (80.1) 195 (85.9) 43 (89.5)
Former 9 (4.8) 6 (2.6) 0 (0)
Current 28 (15.0) 26 (11.4) 5 (10.4)
Alcohol drinking 0.25
Never 168 (90.3) 205 (90.3) 41 (85.4)
Former 11 (5.9) 8 (3.5) 5 (10.4)
Current 7 (3.7) 14 (6.1) 2 (4.1)
Tumor location 0.016
Head 148 (79.5) 153 (67.4) 41 (85.4)
Body 32 (17.2) 63 (27.7) 7 (14.5)
Tail 6 (3.2) 11 (4.8) 0
Tumor Stage < 0.001
I 24 (12.9) 11 (4.8) 9 (18.7)
II 103 (55.3) 114 (50.2) 32 (66.6)
III 20 (10.7) 56 (24.6) 6 (12.5)
IV 39 (20.9) 46 (20.2) 1 (2.0)
¶ P value for chi-squared test
� Data on body mass index at enrolment is missing for 10 participants
https://doi.org/10.1371/journal.pone.0243511.t004
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Table 5. Association between different demographical, clinical, and therapeutic factors with risk of death from pancreatic cancer.
Characteristic N (%) Adjusted Model 1 † HR (95% CI) Model 1 † P value Adjusted Model 2 ┤ HR (95% CI) Model 2 ┤ P value
Age (years)
Each 10 years increase in age - 1.11 (1.01–1.23) 0.023 1.03 (0.93–1.14) 0.55
Gender
Female 177 (39.2) 1 - 1 -
Male 274 (60.8) 1.31 (1.03–1.66) 0.024 1.05 (0.80–1.38) 0.69
Formal education
Ever 269 (59.6) 1 - 1 -
Never 182 (40.3) 1.19 (0.95–1.49) 0.12 0.93 (0.72–1.20) 0.60
Marital status
Married 370 (82.0) 1 - 1 -
Single 81 (17.9) 1.50 (1.11–2.01) 0.0065 1.10 (0.81–1.49) 0.50
Residence
Urban 361 (80.0) 1 - 1 -
Rural 90 (19.9) 1.22 (0.95–1.58) 0.11 1.33 (1.01–1.74) 0.033
Body Mass Index
Normal 190 (42.1) 1 - 1 -
Underweight 12 (2.6) 1.11 (0.59–2.06) 0.73 0.48 (0.18–1.30) 0.17
Overweight 166 (36.8) 0.78 (0.63–0.98) 0.037 0.88 (0.64–1.21) 0.45
Obese 83 (18.4) 0.70 (0.52–0.94) 0.020 0.90 (0.59–1.35) 0.59
Symptom count
Each Additional symptom - 1.05 (1.01–1.08) 0.0069 1.06 (1.02–1.11) 0.0011
Smoking
Never 288 (63.8) 1 - 1 -
Former 58 (12.8) 0.89 (0.64–1.22) 0.47 0.97 (0.69–1.34) 0.84
Current 105 (23.2) 0.94 (0.72–1.22) 0.65 0.81 (0.59–1.10) 0.19
Opium use
Never 381 (84.4) 1 - 1 -
Former 15 (3.3) 1.54 (0.87–2.71) 0.13 1.50 (0.83–2.74) 0.17
Current 55 (12.2) 1.40 (1.03–1.91) 0.030 1.51 (1.04–2.20) 0.027
Drinking alcohol
Never 404 (89.5) 1 - 1 -
Former 24 (5.3) 0.85 (0.54–1.36) 0.52 0.90 (0.54–1.48) 0.61
Current 23 (5.1) 0.81 (0.51–1.28) 0.38 0.71 (0.47–1.28) 0.32
Tumor location
Head 336 (74.5) 1 - 1 -
Body 98 (21.7) 1.22 (0.96–1.55) 0.088 1.33 (1.02–1.75) 0.038
Tail 17 (3.7) 1.14 (0.67–1.96) 0.61 0.91 (0.51–1.65) 0.77
Stage at diagnosis
I 43 (9.5) 1 - 1 -
II 244 (54.1) 1.19 (0.84–1.69) 0.32 1.32 (0.91–1.91) 0.14
III 80 (17.7) 1.29 (0.86–1.93) 0.21 1.51 (0.97–2.34) 0.07
IV 84 (18.6) 2.15 (1.44–3.21) 0.0002 2.07 (1.34–3.19) 0.0012
- Only patients who did not have missing information on any of the presented variables were included in this analysis, and 10 participants who had missing information
on body mass index at enrolment were removed
HR: Hazards Ratio, CI: Confidence Interval
†: This model is adjusted for age, gender, formal education, marital status, and residence.
┤: The fully adjusted model is stratified by the received treatment and simultaneously includes all variables as shown in the table
https://doi.org/10.1371/journal.pone.0243511.t005
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and also the need to provide more education and support to patients who have lower socioeco-
nomic status and are less educated, and also to those single patients who might feel less sup-
ported compared to patients who live with a partner.
In our study having more symptoms at diagnosis was an independent predictor of survival
in PC patients. Consistent with our findings several retrospective studies have also suggested
the prognostic effects of the number of symptoms upon diagnosis of PC [25–27]. Further, we
found that abdominal pain was associated with diagnosis at higher stages, while jaundice, urine
discoloration, and pruritus were associated with diagnosis at lower stages. Although abdominal
is the most common symptom of pancreatic cancer, it is very nonspecific and therefore focusing
only this symptom may lead to a delayed diagnosis of PC [8, 28]. However, patients who have
obstructive jaundice and its associated symptoms are usually referred for thorough investiga-
tions and therefore are diagnosed earlier than patients with the nonspecific symptoms [25, 28,
29]. This was also documented in a systematic review of pancreatic cancer symptoms that
found jaundice to have the highest positive predictive value for the diagnosing PC [29]. In two
case-control studies, patients with PC were reported to have visited the primary healthcare cen-
ters on a median of 18 and 26 times before receiving the correct diagnosis [28, 30]. These find-
ings show the requirement for raising awareness among primary healthcare providers to
consider the diagnosis of PC in high risk older individuals with chronic non-specific symptoms.
In the current study patients who had tumors located in the head of pancreas were diag-
nosed at an earlier stage and had better survival than patients who had tumors located in the
body and tail of pancreas. Several studies have shown that tumor location can affect the sur-
vival of PC patients [25, 31, 32], with tumors that are located in the head having the best prog-
nosis as these patients often develop jaundice and present at early stages of the disease, while
those with distal lesions often have nonspecific symptoms and remain undiagnosed until
advanced stages [25, 30–32].
In this study having an advanced stage tumor was an independent risk factor for mortality.
Further, while our study was an observational study that did not aim to assess the effects of dif-
ferent treatments on PC mortality, we found a better overall survival in patients who under-
went surgery and received chemotherapy compared to those who only received palliative
(symptomatic) treatment. The effects of stage at diagnosis, and surgical resection of the tumor
on the survival of PC are well described in many studies [4, 8, 33]. Although in the available
studies chemotherapy has been shown some beneficial effects on the short-term survival of PC
patients [34], poor response to chemotherapy remains a serious problem in managing PC
patients who have unresectable tumors and further efforts are needed to improve the long-
term survival in these patients [3, 19].
To our knowledge our study is the first prospective study to show the independent effect of
using opium on PC survival. Several retrospective studies have shown the vicious effects of opi-
oid use on survival time in different cancer types including PC [35], gastric cancer [36], and
lung cancer [37]. In two other retrospective studies of patients with advanced incurable can-
cers opioid use was independently associated with shorter survival [38, 39]. Many experimen-
tal studies have documented the tumor promoting effects of opioids that are important for
tumor growth, invasiveness and metastasis [40]; these effects include activating angiogenesis
and neovascularization [40], facilitating cancer cell proliferation and migration [40], and
impairing immune functions [41]. Additionally, opioid receptors have been found in PC tis-
sues and the experimental studies have shown that inhibiting these receptors results in the
inhibition of PC progression [42, 43], as the development and progression of PC are shown to
be related to opioid receptor pathways [42, 44].
The main strengths of this study are being the largest prospective survival study of pancre-
atic cancer in western Asia and Northern Africa, the first prospective study that assesses the
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effect of using opium on PC survival, having actively followed-up PC patients from different
provinces of the country on monthly basis, not having any loss to follow-up, and not having
any missing clinical and pathologic information from any patient. The main limitation of this
study was using EUS and conventional CT scan for evaluating the stage of PC on enrolment.
Spiral CT scan and magnetic resonance imaging (MRI) have better resolutions and are more
accurate in detecting small lesions, and therefore we might have underestimated the stage of
PC in some patients. However, due to the prospective design of this study, any error in mea-
suring PC stage is likely to be non-differential. Another limitation is that we did not gather the
laboratory data including tumor markers and albumin levels for most patients, although the
effect of these factors are controversial, having gathered these information could help in better
understanding of the prognostic factors that affect the survival of PC patients in this region.
Conclusions
Five-year survival rates of PC in Iranian patients are lower than the developed countries.
Besides the stage and pathologic features of PC, socioeconomic characteristics might influence
the probabilities of receiving treatment and survival in these patients. Opium use is a novel
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